220805-35-6

Basic information

• Product Name: 2R-benzyloxymethylpentanoic acid diethylamide
• Synonyms: 2R-benzyloxymethylpentanoic acid diethylamide
• CAS NO: 220805-35-6
• Molecular Weight: 277.407
• Mol File: 220805-35-6.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: 2R-benzyloxymethylpentanoic acid diethylamide(CAS DataBase Reference)
• NIST Chemistry Reference: 2R-benzyloxymethylpentanoic acid diethylamide(220805-35-6)
• EPA Substance Registry System: 2R-benzyloxymethylpentanoic acid diethylamide(220805-35-6)

Safety Data

• Hazardous Substances Data: 220805-35-6(Hazardous Substances Data)

Upstream product

• 100-51-6 benzyl alcohol 
• 220805-27-6 3-(3-benzyloxymethyl-2R-n-propylpropionyl)-4S-benzyloxazolidin-2-one 
• 143868-89-7 3-(1-oxopentyl)-4(S)-(phenylmethyl)-2-oxazolidinone 
• 638-29-9 n-valeryl chloride 
• 3587-60-8 Benzyloxymethyl chloride 
• 109-89-7 diethylamine 
• 220805-31-2 2R-benzyloxymethylpentanoic acid 

Downstream Products

• 220805-49-2 3-(5S-isopropyl-4S-methoxycarbonyl-2-phenyl-4,5-dihydrooxazol-4-yl)-3S-hydroxy-2R-n-propyl-N,N-diethylpropionamide 
• 211866-70-5 [1R-[1S,4R,5S]]-1-(1-hydroxy-2-methylpropyl)-4-n-propyl-6-oxa-2-azabicyclo[3.2.0]heptane-3,7-dione 

Relevant articles and documents

A novel and efficient synthesis of a highly active analogue of clasto-lactacystin β-lactone

Herein, we describe a new convergent synthesis of a more potent analogue of clasto-lactacystin β-lactone (2), PS-519 compound 4, which is currently in preclinical development for the treatment of ischemia-reperfusion injury in stroke and myocardial infarction. The synthetic strategy relies on building two intermediates (an oxazoline and an aldehyde) which are joined through a doubly diastereoselective aldol reaction, setting up the requisite unichiral centers in the final product (4). The facial selectivity and ultimate stereocontrol are achieved by employing a trivalent aluminum Lewis acid, Me2AlCl, in a chelation-induced reaction which yields a single aldol adduct. The efficiency of the synthetic approach has allowed for the preparation of multigram quantities of clinical grade material, which will support Phase I studies.